Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) and Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.
Profitability
This table compares Aldeyra Therapeutics and Indaptus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aldeyra Therapeutics | N/A | -63.75% | -41.27% |
| Indaptus Therapeutics | N/A | -939.67% | -293.64% |
Risk and Volatility
Aldeyra Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aldeyra Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
| Indaptus Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Aldeyra Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 227.38%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Aldeyra Therapeutics is more favorable than Indaptus Therapeutics.
Institutional & Insider Ownership
59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.6% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Aldeyra Therapeutics and Indaptus Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aldeyra Therapeutics | N/A | N/A | -$33.85 million | ($0.57) | -2.95 |
| Indaptus Therapeutics | N/A | N/A | -$20.85 million | ($24.13) | -0.07 |
Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aldeyra Therapeutics beats Indaptus Therapeutics on 8 of the 11 factors compared between the two stocks.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
